HONG KONG – China's Zai Lab Ltd. has returned the exclusive sales license of lung cancer drug Olita Tab (olmutinib) to its developer, South Korea's Hanmi Pharmaceutical Co. Ltd., a move Zai attributed to reprioritization, though Olita Tab has run into problems in clinical studies.
